Lymphoma, Internal medicine, Pathology, Rituximab and Surgery are his primary areas of study. His Lymphoma research is multidisciplinary, relying on both Cancer and Cancer research. The Internal medicine study combines topics in areas such as Gastroenterology and Oncology.
He has researched Pathology in several fields, including Chlamydiaceae and Anemia. His study on Rituximab is covered under Immunology. His study on Chemotherapy, Regimen and Phases of clinical research is often connected to Standard treatment as part of broader study in Surgery.
His main research concerns Internal medicine, Lymphoma, Rituximab, Diffuse large B-cell lymphoma and Oncology. His Internal medicine study combines topics from a wide range of disciplines, such as Gastroenterology and Surgery. His Lymphoma research is multidisciplinary, incorporating elements of Cancer research and Radiation therapy.
In his research, Prednisone is intimately related to Vincristine, which falls under the overarching field of Rituximab. His study in Diffuse large B-cell lymphoma is interdisciplinary in nature, drawing from both Germinal center, BCL6, Gene expression profiling, CHOP and Aggressive lymphoma. His Oncology research integrates issues from Survival rate, ThioTEPA, Lenalidomide and Transplantation.
Andrés J.M. Ferreri focuses on Internal medicine, Lymphoma, Oncology, Diffuse large B-cell lymphoma and Rituximab. His Internal medicine study frequently links to adjacent areas such as Gastroenterology. Andrés J.M. Ferreri specializes in Lymphoma, namely Primary mediastinal B-cell lymphoma.
His Oncology research is multidisciplinary, incorporating perspectives in Primary central nervous system lymphoma, Chemotherapy, Immunotherapy, Chemoimmunotherapy and Radiation therapy. His Diffuse large B-cell lymphoma study is concerned with the larger field of Pathology. His Rituximab study integrates concerns from other disciplines, such as Regimen, Surgery, Transplantation and Vincristine, Cyclophosphamide.
Andrés J.M. Ferreri mostly deals with Lymphoma, Internal medicine, Rituximab, Oncology and Diffuse large B-cell lymphoma. His research integrates issues of Immune checkpoint, Positron emission tomography, Cancer research and Randomized controlled trial in his study of Lymphoma. His research links Surgery with Internal medicine.
His studies deal with areas such as Gastroenterology, Regimen and Vincristine as well as Rituximab. His work is dedicated to discovering how Oncology, Chemotherapy are connected with Vascular permeability, Blood–brain barrier and Meta-analysis and other disciplines. His Diffuse large B-cell lymphoma study improves the overall literature in Pathology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Prognostic Scoring System for Primary CNS Lymphomas: The International Extranodal Lymphoma Study Group Experience
Andrés J M Ferreri;Jean Yves Blay;Michele Reni;Felice Pasini.
Journal of Clinical Oncology (2003)
High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial.
Andrés J. M. Ferreri;Michele Reni;Marco Foppoli;Maurizio Martelli.
The Lancet (2009)
Evidence for an Association Between Chlamydia psittaci and Ocular Adnexal Lymphomas
Andrés J. M. Ferreri;Massimo Guidoboni;Maurilio Ponzoni;Carlo De Conciliis.
Journal of the National Cancer Institute (2004)
Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue.
Emanuele Zucca;Annarita Conconi;Ennio Pedrinis;Sergio Cortelazzo.
Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the 'cutaneous variant'.
Andrés J. M. Ferreri;Elías Campo;John F. Seymour;Rein Willemze.
British Journal of Haematology (2004)
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
Shimin Hu;Zijun Y. Xu-Monette;Alexander Tzankov;Tina Green.
Definition, Diagnosis, and Management of Intravascular Large B-Cell Lymphoma: Proposals and Perspectives From an International Consensus Meeting
Maurilio Ponzoni;Andrés J.M. Ferreri;Elías Campo;Fabio Facchetti.
Journal of Clinical Oncology (2007)
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.
Andrés J M Ferreri;Kate Cwynarski;Elisa Pulczynski;Maurilio Ponzoni.
The Lancet Haematology (2016)
Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type
Annarita Conconi;Giovanni Martinelli;Catherine Thiéblemont;Andrés J M Ferreri.
Diffuse large B-cell lymphoma.
Maurizio Martelli;Andrés J.M. Ferreri;Claudio Agostinelli;Alice Di Rocco.
Critical Reviews in Oncology Hematology (2013)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: